180 Tablets ( SKU: 9521, NPN: 80055115 )
- Provides clinically relevant doses of N-acetyl-L-cysteine and alpha-lipoic acid
- NAC and ALA have direct antioxidant action, and also enhance the synthesis and regeneration of glutathione, the key cellular antioxidant
- Support mitochondrial function as well as phase 2 antioxidant enzyme upregulation
- Improves endothelial function and also supports nitric oxide synthesis Reduce hyperglycemia associated damage
N-acetylcysteine (NAC) and alpha-lipoic acid (ALA) are highly complementary nutrients, critical to cellular function and protection, and management of hyperglycemia associated damage. NAC drives the synthesis of the cellular antioxidant glutathione, often depleted in diabetes, cardiovascular disease, and those with increased oxidative stress.1,2 Additionally, glutathione is needed for the detoxification of many persistent organic pollutants, which have emerged as powerful contributors to diabetes and the metabolic syndrome.3 Clinical trials have shown that NAC restores intraplatelet glutathione levels among diabetics, a marker of atherothrombotic risk, and reduces homocysteine and improves endothelial function in coronary artery disease.4,5,6
ALA, in turn, recycles antioxidant nutrients such as vitamin C and glutathione, and is a cofactor for several mitochondrial enzymes as well as glutathione reductase.7 It improves glycemic control and insulin sensitivity in type 2 diabetics, endothelial function among individuals with impaired glucose tolerance, and enhances weight loss among obese subjects.8,9,10 It has a well-recognized benefit for the prevention and treatment of peripheral neuropathy among diabetics, improving both symptoms and objective markers of disease, such as nerve conduction velocity.11,12 Its antioxidant and neuroprotective effects may also provide protection against neurodegeneration, and a range of oxidant-associated diseases.13,14
Serving Size: 2 Tablets
Servings per Container: 90
Each Tablet Contains:
Alpha-Lipoic Acid.................................................................300 mg
Microcrystalline cellulose, dibasic calcium phosphate dihydrate, stearic acid, vegetable grade magnesium stearate (lubricant), coating (carbohydrate gum [cellulose], glycerin), silica, croscarmellose sodium.
Contains no artificial colours, preservatives, or sweeteners; no dairy, starch, sugar, wheat, gluten, yeast, soy, corn, egg, fish, shellfish, salt, tree nuts, or GMOs. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.
2 tablets per day with meals or as directed by a health care practitioner.
Consult a health care practitioner prior to use if you are pregnant or breastfeeding, or if you have diabetes or kidney stones. Do not use this product if you are taking antibiotics or nitroglycerin. Avoid use with acetylcysteine allergy, and use with caution in individuals with asthma. Keep out of reach of children.
ALA was shown to prevent drug-induced weight gain associated with atypical antipsychotics without reducing drug efficacy.15 Caution should be used with anti-diabetes medications, as they may have additive hypoglycemic effects. Long term use may warrant low dose copper and/or thiamine supplementation. Although NAC may reduce nitroglycerin tolerance and improve its efficacy for unstable angina, severe headaches and hypotension may occur. NAC may also reduce the capacity of activated charcoal to absorb acetaminophen.
- Rushworth GF1, Megson IL2. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014 Feb;141(2):150-9
- Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther. 2008 Dec;8(12):1955-62.
- Lee DH, Lee IK, Song K, Steffes M, et al. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care. 2006 Jul;29(7):1638-44.
- Yilmaz H, Sahin S, Sayar N, et al. Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease. Acta Cardiol. 2007 Dec;62(6):579-85.
- Treweeke AT1, Winterburn TJ, Mackenzie I, et al. N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. Diabetologia. 2012 Nov;55(11):2920-8.
- Tan KS1, Lee KO, Low KC et al. Glutathione deficiency in type 2 diabetes impairs cytokine responses and control of intracellular bacteria. J Clin Invest. 2012 Jun;122(6):2289-300.
- Liu J.The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res. 2008 Jan;33(1):194-203.
- Xiang G, Pu J, Yue L, et al. α-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose. Metabolism. 2011 Apr;60(4):480-5.
- Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens). 2006 Oct-Dec;5(4):251-8.
- Koh EH, Lee WJ, Lee SA, et al. Effects of alpha-lipoic Acid on body weight in obese subjects. Am J Med. 2011 Jan;124(1):85.e1-8.
- Han T, Bai J, Liu W, et al. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012 Oct;167(4):465-71.
- Tang J, et al. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007 May;13(3):164-7.
- Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70.
- Sun YD, Dong YD, Fan R, et al.Effect of (R)-α-lipoic acid supplementation on serum lipids and antioxidative ability in patients with age-related macular degeneration. Ann Nutr Metab. 2012;60(4):293-7.
- Kim E, Park DW, et al. A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. J Clin Psychopharmacol. 2008 Apr;28(2):138-46.